Pharmacokinetic drug interactions involving Ginkgo biloba

References

• Abourashed EA, Khan IA. (2001). High-performance liquid chromatography determination of hydrastine and berberine in dietary supplements containing goldenseal. J Pharm Sci 90:817–822
   PubMed Web of Science ®Google Scholar
• Almond LM, Hoggard PG, Edirisinghe D, et al. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 56:738–744
   PubMed Web of Science ®Google Scholar
• Argikar UA, Remmel RP. (2009). Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 37:229–236
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK, Leake BF, Kim RB. (2007). Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 81:495–502
   PubMed Web of Science ®Google Scholar
• Baron-Ruppert G, Luepke NP. (2001). Evidence for toxic effects of alkylphenols from Ginkgo biloba in the hen’s egg test (HET). Phytomedicine 8:133–138
   PubMed Web of Science ®Google Scholar
• Bedir E, Tatli II, Khan RA, et al. (2002). Biologically active secondary metabolites from Ginkgo biloba. J Agric Food Chem 50:3150–3155
   PubMed Web of Science ®Google Scholar
• Benet LZ. (2009). The drug transporter-metabolism alliance: Uncovering and defining the interplay. Mol Pharm 6:1631–1643
   PubMed Web of Science ®Google Scholar
• Benet LZ, Izumi T, Zhang Y, et al. (1999). Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 62:25–31
   PubMed Web of Science ®Google Scholar
• Biber A. (2003). Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 36:S32–S37
   PubMed Web of Science ®Google Scholar
• Biber A, Koch E. (1999). Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS. Planta Med 65:192–193
   PubMed Web of Science ®Google Scholar
• Blumenthal M, Busse WR, Goldberg A, et al. (1998). The complete German Commission E monographs: Therapeutic guide to herbal medicines. Austin, TX: American Botanical Council; Boston (MA)
   Google Scholar
• Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. (2000). An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7:273–282
   PubMed Web of Science ®Google Scholar
• Butterweck V, Derendorf H, Gaus W, et al. (2004). Pharmacokinetic herb--drug interactions: Are preventive screenings necessary and appropriate? Planta Med 70:784–791
   PubMed Web of Science ®Google Scholar
• Chang TK, Chen J, Teng XW. (2006). Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by Ginkgo biloba extract in cultured hepatocytes. Drug Metab Dispos 34:234–242
   PubMed Web of Science ®Google Scholar
• Chang TK, Gonzalez FJ, Waxman DJ. (1994). Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437–442
   PubMed Web of Science ®Google Scholar
• Chatterjee SS, Doelman CJ, Nöldner M, et al. (2005). Influence of the Ginkgo extract EGb 761 on rat liver cytochrome P450 and steroid metabolism and excretion in rats and man. J Pharm Pharmacol 57:641–650
   PubMed Web of Science ®Google Scholar
• Chauhan B, Yu C, Krantis A, et al. (2007). In vitro activity of uva-ursi against cytochrome P450 isoenzymes and P-glycoprotein. Can J Physiol Pharmacol 85:1099–1107
   PubMed Web of Science ®Google Scholar
• Chen YC, Gotzkowsky SK, Nafziger AN, et al. (2006). Poor correlation between 6beta-hydroxycortisol: Cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Br J Clin Pharmacol 62:187–195
   PubMed Web of Science ®Google Scholar
• Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. (2003). A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 36:1585–1592
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, et al. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–871
   PubMed Web of Science ®Google Scholar
• DAB 2003. (2003). Monographie Eingestellter Ginkgotrockenextrakt, Deutsches Arzneibuch 2003. Stuttgart, Deutscher Apotheker-Verlag
   Google Scholar
• DeKosky ST, Williamson JD, Fitzpatrick AL, et al. (2008). Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 300:2253–2262
   PubMed Web of Science ®Google Scholar
• Deng Y, Bi HC, Zhao LZ, et al. (2008a). Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica 38:465–481
   PubMed Web of Science ®Google Scholar
• Deng Y, Bi HC, Zhao LZ, et al. (2008b). Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab Lett 2:60–66
   PubMedGoogle Scholar
• Dirson G, Fernandez C, Hindlet P, et al. (2006). Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res 23:1525–1532
   PubMed Web of Science ®Google Scholar
• Drago F, Floriddia ML, Cro M, Giuffrida S. (2002). Pharmacokinetics and bioavailability of a Ginkgo biloba extract. J Ocul Pharmacol Ther 18:197–202
   PubMed Web of Science ®Google Scholar
• Dresser GK, Kim RB, Bailey DG. (2005). Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77:170–177
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Reetz KP, Schmidt EK, Zekorn C. (1986). The genetic polymorphism of sparteine metabolism. Xenobiotica 16:465–481
   PubMed Web of Science ®Google Scholar
• EMA. (2010). Guideline on the investigation of bioequivalence. Committee for human medicinal products, European Medicines Agency, London
   Google Scholar
• EMA. (2012). Guideline on the investigation of drug interactions. Committee for human medicinal products, European Medicines Agency, London
   Google Scholar
• Engelsen J, Nielsen JD, Winther K. (2002). Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost 87:1075–1076
   PubMed Web of Science ®Google Scholar
• ESCOP. (2003). Ginkgo Folium, Ginkgo Leaf. In: ESCOP ed. ESCOP Monographs, 2nd edition. Stuttgart, New York: Thieme, 178–210
   Google Scholar
• Etheridge AS, Black SR, Patel PR, et al. (2007). An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73:731–741
   PubMed Web of Science ®Google Scholar
• Fan L, Mao XQ, Tao GY, et al. (2009a). Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 39:249–254
   PubMed Web of Science ®Google Scholar
• Fan L, Tao GY, Wang G, et al. (2009b). Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother 43:944–949
   PubMed Web of Science ®Google Scholar
• Flexner C. (2000). Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 40:649–674
   PubMed Web of Science ®Google Scholar
• Fourtillan JB, Brisson AM, Girault J, et al. (1995). Propriétés pharmacocinetiques du bilobalide et des ginkgolides A et B chez le sujet sain près administrations intraveineuses et orales d’extrait de Ginkgo biloba (EGb 761®). Therapie 50:137–144
   PubMedGoogle Scholar
• Frank A, Unger M. (2006). Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 1112:255–262
   PubMed Web of Science ®Google Scholar
• Fuchikami H, Satoh H, Tsujimoto M, et al. (2006). Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 34:577–582
   PubMed Web of Science ®Google Scholar
• Galluzzi S, Zanetti O, Binetti G, et al. (2000). Coma in a patient with Alzheimer’s disease taking low dose trazodone and gingko biloba. J Neurol Neurosurg Psychiatry 68:679–680
   PubMed Web of Science ®Google Scholar
• Galteau MM, Shamsa F. (2003). Urinary 6beta-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713–733
   PubMed Web of Science ®Google Scholar
• Gaudineau C, Beckerman R, Welbourn S, Auclair K. (2004). Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 318:1072–1078
   PubMed Web of Science ®Google Scholar
• German Commission E. (1994). Monograph on dry extracts (35–67:1) made of G. biloba leaves. Bundesanzeiger Nr 133. Köln, Germany, Bundesanzeiger Verlagsgesellschaft
   Google Scholar
• Glisson JK, Minor DS, Walker LA, Gurley BJ. (2011). Dietary supplements: Safety issues and quality control. Arch Intern Med 171:476–477
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Luo Y, et al. (2006). Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 46:214–221
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. (2002). Cytochrome P450 phenotypic ratios for predicting herb--drug interactions in humans. Clin Pharmacol Ther 72:276–287
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. (2005a). Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil Panax ginseng and Ginkgo biloba. Drugs Aging 22:525–539
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. (2005b). In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415–426
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Hubbard MA, et al. (2008a). Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 83:61–69
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Hubbard MA, et al. (2008b). Clinical assessment of CYP2D6-mediated herb--drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava St. John’s wort, and Echinacea. Mol Nutr Food Res 52:755–763
   PubMed Web of Science ®Google Scholar
• Hamik A, Peroutka SJ. (1989). 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25:569–575
   PubMed Web of Science ®Google Scholar
• Hanrahan JR, Chebib M, Johnston GA. (2011). Flavonoid modulation of GABA(A) receptors. Br J Pharmacol 163:234–245
   PubMed Web of Science ®Google Scholar
• Hariparsad N, Chu X, Yabut J, et al. (2009). Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes. Nucleic Acids Res 37:1160–1173
   PubMed Web of Science ®Google Scholar
• Hecker H, Johannisson R, Koch E, Siegers CP. (2002). In vitro evaluation of the cytotoxic potential of alkylphenols from Ginkgo biloba L. Toxicology 177:167–177
   PubMed Web of Science ®Google Scholar
• Hellum BH, Nilsen OG. (2008). In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 102:466–475
   PubMed Web of Science ®Google Scholar
• Herrschaft H, Nacu A, Likhachev S, et al. (2012). Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 46:716–723
   PubMed Web of Science ®Google Scholar
• Hu ZY, Zhao YS, Wu D, Cheng ZN. (2009). Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans. Clin Chim Acta 408:92–97
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Balogh LM, Zientek M, et al. (2009). Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/−)-suprofen: A comparison of kinetics and probe substrate selection. Drug Metab Dispos 37:59–65
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. (2003). Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540–547
   PubMed Web of Science ®Google Scholar
• Ihl R, Bachinskaya N, Korczyn AD, et al. (2011). Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: A randomized controlled trial. Int J Geriatr Psychiatry 26:1186–1194
   PubMed Web of Science ®Google Scholar
• Imanaga J, Kotegawa T, Imai H, et al. (2011). The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics 21:84–93
   PubMed Web of Science ®Google Scholar
• Jäger AK, Saaby L. (2011). Flavonoids and the CNS. Molecules 16:1471–1485
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Pradko JF, Muir KT. (2005). Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 27:1685–1695
   PubMed Web of Science ®Google Scholar
• Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. (2003). Voriconazole. Clin Ther 25:1321–1381
   PubMed Web of Science ®Google Scholar
• Jiang X, Williams KM, Liauw WS, et al. (2005). Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 59:425–432
   PubMed Web of Science ®Google Scholar
• Jones SA, Moore LB, Shenk JL, et al. (2000). The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27–39
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. (1997). Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74
   PubMed Web of Science ®Google Scholar
• Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. (1996). Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 24:1081–1087
   PubMed Web of Science ®Google Scholar
• Kehr J, Yoshitake S, Ijiri S, et al. (2012). Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: Possible implications for the cognitive enhancing properties of EGb 761®. Int Psychogeriatr 24:S25–S34
   PubMed Web of Science ®Google Scholar
• Kim BH, Kim KP, Lim KS, et al. (2010). Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: An open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 32:380–390
   PubMed Web of Science ®Google Scholar
• Kimoto E, Chupka J, Xiao Y, et al. (2011). Characterization of digoxin uptake in sandwich-cultured human hepatocytes. Drug Metab Dispos 39:47–53
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, et al. (2005). Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379–386
   PubMedGoogle Scholar
• König J. (2011). Uptake transporters of the human OATP family: Molecular characteristics, substrates, their role in drug--drug interactions, and functional consequences of polymorphisms. Handb Exp Pharmacol 201:1–28
   PubMedGoogle Scholar
• Kressmann S, Biber A, Wonnemann M, et al. (2002a). Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol 54:1507–1514
   PubMed Web of Science ®Google Scholar
• Kressmann S, Müller WE, Blume HH. (2002b). Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 54:661–669
   PubMed Web of Science ®Google Scholar
• Kudolo GB, Wang W, Javors M, Blodgett J. (2006). The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects – A double blind placebo-controlled, crossover study. Clin Nutr 25:606–616
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Ismair MG, Stieger B, et al. (2001). Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525–533
   PubMed Web of Science ®Google Scholar
• Kupiec T, Raj V. (2005). Fatal seizures due to potential herb--drug interactions with Ginkgo biloba. J Anal Toxicol 29:755–758
   PubMed Web of Science ®Google Scholar
• Laine JE, Auriola S, Pasanen M, Juvonen RO. (2009). Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 39:11–21
   PubMed Web of Science ®Google Scholar
• Lau AJ, Yang G, Rajaraman G, et al. (2010). Human pregnane X receptor agonism by Ginkgo biloba extract: Assessment of the role of individual ginkgolides. J Pharmacol Exp Ther 335:771–780
   PubMed Web of Science ®Google Scholar
• Lei HP, Ji W, Lin J, et al. (2009a). Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol 68:201–206
   PubMed Web of Science ®Google Scholar
• Lei HP, Wang G, Wang LS, et al. (2009b). Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother 43:726–731
   PubMed Web of Science ®Google Scholar
• Li L, Stanton JD, Tolson AH, et al. (2009). Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 26:872–882
   PubMed Web of Science ®Google Scholar
• Liu Z, Hu M. (2007). Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol 3:389–406
   PubMed Web of Science ®Google Scholar
• Lu WJ, Huang JD, Lai. ML. (2006). The effects of ergoloid mesylates and Ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol 46:628–634
   PubMed Web of Science ®Google Scholar
• Ma JD, Tsunoda SM, Bertino JS Jr, et al. (2010). Evaluation of in vivo P-glycoprotein phenotyping probes: A need for validation. Clin Pharmacokinet 49:223–237
   PubMed Web of Science ®Google Scholar
• Madsen H, Enggaard TP, Hansen LL, et al. (2001). Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 69:41–47
   PubMed Web of Science ®Google Scholar
• Mandery K, Bujok K, Schmidt I, et al. (2010). Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol 80:1746–1753
   PubMed Web of Science ®Google Scholar
• Markowitz JS, DeVane CL, Lewis JG, et al. (2005). Effect of Ginkgo biloba extract on plasma steroid concentrations in healthy volunteers: A pilot study. Pharmacotherapy 25:1337–1340
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Donovan JL, DeVane CL, et al. (2003). Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 23:576–581
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Hosokawa S, Horie T, et al. (1994). Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 22:909–915
   PubMed Web of Science ®Google Scholar
• Mathews JM, Etheridge AS, Valentine JL, et al. (2005). Pharmacokinetics and disposition of the kavalactone kawain: Interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 33:1555–1563
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Hayashi H, et al. (2008). Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474–1483
   PubMed Web of Science ®Google Scholar
• Mauri P, De Palma A, Pozzi F, et al. (2006). LC-MS characterization of terpene lactones in plasma of experimental animals treated with Ginkgo biloba extracts: Correlation with pharmacological activity. J Pharm Biomed Anal 40:763–768
   PubMed Web of Science ®Google Scholar
• Mauro VF, Mauro LS, Kleshinski JF, et al. (2003). Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 10:247–251
   PubMedGoogle Scholar
• McKenna DJ, Jones K, Hughes K. (2001). Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 7:70–90
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. (1998). Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538
   PubMed Web of Science ®Google Scholar
• Miura M, Kagaya H, Satoh S, et al. (2008). Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 30:559–564
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Inoue K, et al. (2007). Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:1161–1169
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Frye RF. (2010). Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab Dispos 38:270–275
   PubMed Web of Science ®Google Scholar
• Mohutsky MA, Anderson GD, Miller JW, Elmer GW. (2006). Ginkgo biloba: Evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 13:24–31
   PubMed Web of Science ®Google Scholar
• Nabekura T, Yamaki T, Ueno K, Kitagawa S. (2008). Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol 62:867–873
   PubMed Web of Science ®Google Scholar
• Naccarato M, Yoong D, Gough K. (2012). A potential drug--herbal interaction between Ginkgo biloba and Efavirenz. J Int Assoc Physicians AIDS Care 11:98–100
   Google Scholar
• Nare B, Prichard RK, Georges E. (1994). Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells. Mol Pharmacol 45:1145–1152
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AY. (1995). Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–158
   PubMed Web of Science ®Google Scholar
• Nieder M. (1991). Pharmakokinetik der Ginkgo-Flavonole im Plasma. Münch Med Wschr 133:S61–62
   Google Scholar
• Nowack R, Andrassy J, Fischereder M, Unger M. (2009). Effects of dietary factors on drug transport and metabolism: The impact on dosage guidelines in transplant patients. Clin Pharmacol Ther 85:439–443
   PubMed Web of Science ®Google Scholar
• Numa AM, Abbott FS, Chang TK. (2007). Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype. Can J Physiol Pharmacol 85:848–855
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug--drug interactions. J Pharmacol Exp Ther 316:336–348
   PubMed Web of Science ®Google Scholar
• Ogburn ET, Jones DR, Masters AR, et al. (2010). Efavirenz primary and secondary metabolism in vitro and in vivo: Identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 38:1218–1229
   PubMed Web of Science ®Google Scholar
• Ohnishi N, Kusuhara M, Yoshioka M, et al. (2003). Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 26:1315–1320
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Duret C, et al. (2008). The tangle of nuclear receptors that controls xenobiotic metabolism and transport: Crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1–32
   PubMed Web of Science ®Google Scholar
• PharmEUR. (1999). Ginkgo Dry Extract, standardized. Pharmeuropa 11:333–337
   Google Scholar
• Picard N, Ratanasavanh D, Prémaud A, et al. (2005). Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139–146
   PubMed Web of Science ®Google Scholar
• Picard N, Yee SW, Woillard JB, et al. (2010). The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 87:100–108
   PubMed Web of Science ®Google Scholar
• Pietta PG, Gardana C, Mauri PL. (1997). Identification of Gingko biloba flavonol metabolites after oral administration to humans. J Chromatogr B Biomed Sci Appl 693:249–255
   PubMed Web of Science ®Google Scholar
• Pietta PG, Gardana C, Mauri PL, et al. (1995). Identification of flavonoid metabolites after oral administration to rats of a Ginkgo biloba extract. J Chromatogr B Biomed Appl 673:75–80
   PubMed Web of Science ®Google Scholar
• Prickett KS, Baillie TA. (1984). Metabolism of valproic acid by hepatic microsomal cytochrome P-450. Biochem Biophys Res Commun 122:1166–1173
   PubMed Web of Science ®Google Scholar
• Rajaraman G, Chen J, Chang TK. (2006). Ginkgolide A contributes to the potentiation of acetaminophen toxicity by Ginkgo biloba extract in primary cultures of rat hepatocytes. Toxicol Appl Pharmacol 217:225–233
   PubMed Web of Science ®Google Scholar
• Rangel-Ordóñez L, Nöldner M, Schubert-Zsilavecz M, Wurglics M. (2010). Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761®. Planta Med 76:1683–1690
   PubMed Web of Science ®Google Scholar
• Rengelshausen J, Banfield M, Riedel KD, et al. (2005). Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 78:25–33
   PubMed Web of Science ®Google Scholar
• Rettie AE, Korzekwa KR, Kunze KL, et al. (1992). Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-450 2C9 in the etiology of (S)-warfarin--drug interactions. Chem Res Toxicol 5:54–59
   PubMed Web of Science ®Google Scholar
• Rettie AE, Rettenmeier AW, Howald WN, Baillie TA. (1987). Cytochrome P-450-catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science 235:890–893
   PubMed Web of Science ®Google Scholar
• Robertson SM, Davey RT, Voell J, et al. (2008). Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 24:591–599
   PubMed Web of Science ®Google Scholar
• Rotzinger S, Fang J, Baker GB. (1998). Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 26:572–575
   PubMed Web of Science ®Google Scholar
• Sasaki K, Wada K, Hatta S, et al. (1997). Bilobalide, a constituent of Ginkgo biloba L, potentiates drug-metabolizing enzyme activities in mice: Possible mechanism for anticonvulsant activity against 4-O-methylpyridoxine-induced convulsions. Res Commun Mol Pathol Pharmacol 96:45–56
   PubMed Web of Science ®Google Scholar
• Satsu H, Hiura Y, Mochizuki K, et al. (2008). Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem 56:5366–5373
   PubMed Web of Science ®Google Scholar
• Schmider J, Greenblatt. DJ, von Moltke LL, Shader RI. (1996). Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: Implications for diazepam disposition in humans. J Clin Psychopharmacol 16:267–272
   PubMed Web of Science ®Google Scholar
• Shi C, Liu J, Wu F, Yew DT. (2010). Ginkgo biloba extract in Alzheimer’s disease: From action mechanisms to medical practice. Int J Mol Sci 11:107–123
   PubMed Web of Science ®Google Scholar
• Shinozuka K, Umegaki K, Kubota Y, et al. (2002). Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 70:2783–2792
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. (2011). Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J Pharm Sci 100:3843–3853
   PubMed Web of Science ®Google Scholar
• Shord SS, Cavallari LH, Viana MA, et al. (2008). Cytochrome P450 2C9 mediated metabolism in people with and without cancer. Int J Clin Pharmacol Ther 46:365–374
   PubMed Web of Science ®Google Scholar
• Siegers CP. (1999). Cytotoxicity of alkylphenols from Ginkgo biloba. Phytomedicine 6:281–283
   PubMed Web of Science ®Google Scholar
• Singh B, Kaur P, Gopichand Singh RD, Ahuja PS. (2008). Biology and chemistry of Ginkgo biloba. Fitoterapia 79:401–418
   PubMed Web of Science ®Google Scholar
• Song J, Fang G, Zhang Y, et al. (2010). Fingerprint analysis of Ginkgo biloba leaves and related health foods by high-performance liquid chromatography/electrospray ionization-mass spectrometry. J AOAC Int 93:1798–1805
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Baktir G, Radschuweit A, et al. (1998). P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16–24
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kubota Y, Shinozuka K, et al. (2004). Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats. Life Sci 75:1113–1122
   PubMed Web of Science ®Google Scholar
• Taki Y, Hagiwara E, Hirose C, et al. (2011). Effects of Ginkgo biloba extract on the pharmacokinetics and pharmacodynamics of tolbutamide in protein-restricted rats. J Pharm Pharmacol 63:1238–1243
   PubMed Web of Science ®Google Scholar
• Taki Y, Yamazaki Y, Shimura F, et al. (2009). Time-dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats. J Pharmacol Sci 109:459–462
   PubMed Web of Science ®Google Scholar
• Taki Y, Yokotani K, Yamada S, et al. (2012). Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice. Phytomedicine 19:177–182
   PubMed Web of Science ®Google Scholar
• Tamasi V, Juvan P, Beer M, et al. (2009). Transcriptional activation of PPAR alpha by phenobarbital in the absence of CAR and PXR. Mol Pharm 6:1573–1581
   PubMedGoogle Scholar
• Tang J, Sun J, Zhang Y, et al. (2007). Herb--drug interactions: Effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats. Food Chem Toxicol 45:2441–2445
   PubMed Web of Science ®Google Scholar
• Tang D, Yang D, Tang A, et al. (2010). Simultaneous chemical fingerprint and quantitative analysis of Ginkgo biloba extract by HPLC-DAD. Anal Bioanal Chem 396:3087–3095
   PubMed Web of Science ®Google Scholar
• Taub ME, Mease K, Sane RS, et al. (2011). Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. Drug Metab Dispos 39:2093–2102
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. (1998). Metabolism and elimination of 14C-donepezil in healthy volunteers: A single-dose study. Br J Clin Pharmacol 46:19–24
   PubMed Web of Science ®Google Scholar
• Uchida S, Yamada H, Li XD, et al. (2006). Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 46:1290–1298
   PubMed Web of Science ®Google Scholar
• Umegaki K, Taki Y, Endoh K, et al. (2007). Bilobalide in Ginkgo biloba extract is a major substance inducing hepatic CYPs. J Pharm Pharmacol 59:871–877
   PubMed Web of Science ®Google Scholar
• Unger M. (2010). Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance. Wien Med Wochenschr 160:571–577
   PubMedGoogle Scholar
• Unger M. (2011). Pharmacokinetic drug interactions between anticancer therapeutics and drugs of complementary medicine: Mechanisms and clinical relevance. Forsch Komplementmed 18:213–218
   PubMedGoogle Scholar
• Unger M, Frank A. (2004). Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 18:2273–2281
   PubMed Web of Science ®Google Scholar
• Unger M, Holzgrabe U, Jacobsen W, et al. (2002). Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med 68:1055–1058
   PubMed Web of Science ®Google Scholar
• Unger M, Laug S, Holzgrabe U. (2005). Capillary zone electrophoresis as a tool for the quality control of goldenseal extracts. Electrophoresis 26:2430–2436
   PubMed Web of Science ®Google Scholar
• USP. (2008). Powdered ginkgo extract. In: The United States Pharmacopeial Convention Inc. Monograph Powdered Ginkgo Extract USP 32:1019–1021
   Google Scholar
• van Beek TA, Montoro P. (2009). Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J Chromatogr A 1216:2002–2032
   PubMed Web of Science ®Google Scholar
• Veronese ME, Miners JO, Randles D, et al. (1990). Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403–411
   PubMed Web of Science ®Google Scholar
• Verschraagen M, Koks CH, Schellens JH, Beijnen J. (1999). P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. Pharmacol Res 40:301–306
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Weemhoff JL, Bedir E, et al. (2004). Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 56:1039–1044
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Weemhoff JL, Perloff MD, et al. (2002). Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos 23:361–367
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–660
   PubMed Web of Science ®Google Scholar
• Wang DL, Liang Y, Chen WD, et al. (2008a). Identification of ginkgolide B metabolites in urine and rat liver cytochrome P450 enzymes responsible for their formation in vitro. Acta Pharmacol Sin 29:376–384
   PubMed Web of Science ®Google Scholar
• Wang J, Figurski M, Shaw LM, Burckart GJ. (2008b). The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl Immunol 19:192–196
   PubMed Web of Science ®Google Scholar
• Watanabe CM, Wolffram S, Ader P, et al. (2001). The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc Natl Acad Sci USA 98:6577–6580
   PubMed Web of Science ®Google Scholar
• Watkins PB. (1994). Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171–184
   PubMedGoogle Scholar
• Weiss J, Ten Hoevel MM, Burhenne J, et al. (2009). CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 49:196–204
   PubMed Web of Science ®Google Scholar
• WHO. (1999). Folium Ginkgo. In: WHO. WHO monographs on selected medicinal plants, volume 1. Geneva: World Health Organization, 154–167
   Google Scholar
• Wiegman DJ, Brinkman K, Franssen EJ. (2009). Interaction of Ginkgo biloba with efavirenz. AIDS 23:1184–1185
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, et al. (2004). Drug--drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–1208
   PubMed Web of Science ®Google Scholar
• Winzer R, Langmann P, Zilly M, et al. (2003). No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 8:531–534
   PubMed Web of Science ®Google Scholar
• Woelkart K, Feizlmayr E, Dittrich P, et al. (2010). Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res 24:445–450
   PubMed Web of Science ®Google Scholar
• Xie J, Ding C, Ge Q, et al. (2008). Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. J Chromatogr B 864:87–94
   PubMed Web of Science ®Google Scholar
• Xin HW, Wu XC, Li Q, et al. (2009). Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers. Br J Clin Pharmacol 67:541–546
   PubMed Web of Science ®Google Scholar
• Xin HW, Wu XC, Li Q, et al. (2007). Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol 64:469–475
   PubMed Web of Science ®Google Scholar
• Yale SH, Glurich I. (2005). Analysis of the inhibitory potential of Ginkgo biloba. Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 11:433–439
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Shaw PM, et al. (1997). Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434–442
   PubMed Web of Science ®Google Scholar
• Yang TJ, Shou M, Korzekwa KR, et al. (1998). Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol 55:889–896
   PubMed Web of Science ®Google Scholar
• Yang XF, Wang NP, Lu WH, Zeng FD. (2003). Effects of Ginkgo biloba extract and tanshinone on cytochrome P-450 isozymes and glutathione transferase in rats. Acta Pharmacol Sin 24:1033–1038
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Furukori H, Kaneda A, et al. (2004). The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 44:538–542
   PubMed Web of Science ®Google Scholar
• Yeung EY, Sueyoshi T, Negishi M, Chang TK. (2008). Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 36:2270–2276
   PubMed Web of Science ®Google Scholar
• Yin OQ, Lam SS, Lo CM, Chow MS. (2004a). Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: Application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom 18:2921–2933
   PubMed Web of Science ®Google Scholar
• Yin OQ, Tomlinson B, Waye MM, et al. (2004b). Pharmacogenetics and herb--drug interactions: Experience with Ginkgo biloba and omeprazole. Pharmacogenetics 14:841–850
   PubMedGoogle Scholar
• Yoshioka M, Ohnishi N, Koishi T, et al. (2004). Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 27:2006–2009
   PubMed Web of Science ®Google Scholar
• Yu C, Chai X, Yu L, et al. (2011). Identification of novel pregnane X receptor activators from traditional Chinese medicines. J Ethnopharmacol 136:137–143
   PubMed Web of Science ®Google Scholar
• Yueh MF, Mellon PL, Tukey RH. (2011). Inhibition of human UGT2B7 gene expression in transgenic mice by the constitutive androstane receptor. Mol Pharmacol 79:1053–1060
   PubMed Web of Science ®Google Scholar
• Zadoyan G, Rokitta D, Klement S, et al. (2012). Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: A cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol 68:553–560
   PubMed Web of Science ®Google Scholar
• Zhao LZ, Huang M, Chen J, et al. (2006). Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats. Curr Drug Metab 7:577–587
   PubMed Web of Science ®Google Scholar
• Zhou C, Poulton EJ, Grün F, et al. (2007). The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220–229
   PubMed Web of Science ®Google Scholar
• Zhou HH. (2001). CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta 313:203–208
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Li SC, et al. (2004). Predicting pharmacokinetic herb--drug interactions. Drug Metabol Drug Interact 20:143–158
   PubMedGoogle Scholar
• Zou L, Harkey MR, Henderson GL. (2002). Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products. Phytomedicine 9:263–267
   PubMed Web of Science ®Google Scholar
• Zuo XC, Zhang BK, Jia SJ, et al. (2010). Effects of Ginkgo biloba extracts on diazepam metabolism: A pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 66:503–509
   PubMed Web of Science ®Google Scholar